U-Blot® Research Grade Afasevikumab

Name: U-Blot® Research Grade Afasevikumab
SKU: WA1033
Availability: InStock

$9,999.00

Size:50ug

SKU: WA1033-50

Catalog No.: WA1033

Specification: 50ug/100ug

Stock: In stock

Product details, specifications, documents, and related products are available from the catalog record. Learn more

Product details Specifications Q & A Education

Product details, specifications, documents, and related products are available from the catalog record.

Product Overview

Catalog No.: WA1033
SKU: WA1033-50
Category: Biosimilar Antibodies
Product Type: Other
Size: 50ug/100ug
Stock Status: In stock
Available Stock: 999
Minimum Order Quantity: 1

Storage & Compliance

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Research Use Only: Yes

Additional Specifications

PackSize: 50ug/100ug
Target: CTLA-8
Reactivity: Human
Applications: ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host Species: Human
Isotype: IgG1-kappa
Conjugate/Modification: --
Recommended Dilution Ratio: --
Composition: 0.01M PBS, pH 7.4.
Purification Process: Protein A/G purified from cell culture supernatant.
Purity: >95% as determined by SDS-PAGE.
storageCondition: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clonality: Monoclonal
Clone Number: --
Immunogen: Mammalian Cells
Alias: CTLA-8, Cytotoxic T-lymphocyte-associated antigen 8, IL17, IL-17A, IL17A, CTLA8, IL-17, Interleukin-17A, IL17F, Interleukin-17F, IL-17F, Cytokine ML-1
Species: --
Gene ID-1: Q16552 & Q96PD4
Uniprot: --
Background: Afasevikumab, also known as RG7624, is a human antibody inhibitor for human interleukin 17A (IL17A) and interleukin 17F (IL17F). This drug was developed by Genentech and has been investigated in the study of the treatment of inflammation diseases like autoimmune disorders. In 2013, Genentech completed a phase Ib study for the treatment of autoimmune disorders in Canada. However, it had been discontinued in 2015. In 2016, researchers used afasevikumab to conduct a phase I clinical trials for the treatment of inflammation in USA with no specified. • IL-17 and IL-17-producing cells in protection versus pathology., PMID:35790881 • The IL-17 Family of Cytokines in Health and Disease., PMID:30995505 • The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond., PMID:30127781 • Functional specialization of interleukin-17 family members., PMID:21349428 • Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease., PMID:31866067 • The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases., PMID:37600764 • The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis., PMID:30109481 • Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies., PMID:37373452 • Rhythmic IL-17 production by γδ T cells maintains adipose de novo lipogenesis., PMID:39478228 • Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation., PMID:29275332
Tissue Expression: --
Signaling_pathway: --
Research Areas: --

Tech Support

ucallm

Documents

Datasheet, COA, SDS, and protocol files can be requested from technical support.

Storage & Handling

Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.